[144] REGENXBIO Inc. SEC Filing

Rhea-AI Filing Summary

REGENXBIO Inc. (RGNX) filed a Form 144 notifying the proposed sale of 15,358 shares of its common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $151,890.62 and an approximate planned sale date of 09/10/2025 on NASDAQ.

The shares were acquired as Restricted Stock Units from the issuer on 01/01/2023 and total outstanding shares are reported as 50,514,216, making the planned sale approximately 0.03% of outstanding stock. The filing affirms the signer does not possess undisclosed material adverse information and indicates no securities were sold in the past three months by the reporting person.

Insights

Financial Analyst

TL;DR: Small insider sale disclosed; immaterial to capitalization but relevant for disclosure transparency.

The Form 144 reports a proposed sale of 15,358 shares valued at $151,890.62 scheduled for 09/10/2025 through Morgan Stanley Smith Barney LLC. Given the issuer's reported 50,514,216 shares outstanding, the position represents roughly 0.03% of the float, which is not material to company valuation or liquidity. The shares originated as Restricted Stock Units issued on 01/01/2023, indicating this is likely a planned monetization of compensation rather than a change in control or unexpected divestiture. No shares were sold in the prior three months according to the filing, and the filer affirms absence of undisclosed material information.

Corporate Governance Expert

TL;DR: Proper disclosure of an insider RSU sale; governance process appears followed.

The notice documents compliance with Rule 144 procedures by disclosing the broker, number of shares, acquisition as RSUs, and planned sale date. The representation that the signer has no undisclosed material adverse information aligns with statutory attestation requirements. The small size of the sale reduces governance concerns about insider signaling, but the filing does not state whether a 10b5-1 plan applies; the form provides space for such a date but leaves it blank, so no explicit trading-plan protection is declared within this notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	15358	151890.62	50514216	09/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/01/2023	Restricted Stock Units	Issuer			15358	01/01/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did REGENXBIO (RGNX) disclose in this Form 144?

The filing discloses a proposed sale of 15,358 common shares valued at $151,890.62, to be executed on 09/10/2025 via Morgan Stanley Smith Barney LLC on NASDAQ.

How and when were the shares being sold by the RGNX filer acquired?

The shares were acquired as Restricted Stock Units from the issuer on 01/01/2023 and the payment is listed as N/A.

What percentage of RGNX outstanding shares does this proposed sale represent?

The filing reports 50,514,216 shares outstanding; the proposed sale of 15,358 shares is approximately 0.03% of outstanding shares.

Did the filer report any securities sold in the past three months?

No. The Form 144 states "Nothing to Report" for securities sold during the past three months by the reporting person.

Does the filing indicate a 10b5-1 trading plan or other trading instruction date?

No explicit 10b5-1 plan adoption or instruction date is provided in the notice; the related field is left blank in the filing.